 |
Overview |
ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines.
Our first product candidate Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, is currently in Phase I clinical development.
Cervical cancer is the second largest cause of cancer deaths in women worldwide. There is a clear, currently unmet, need for an effective therapeutic vaccine for patients with premalignant cervical lesions, so called CIN2/3.
Prophylactic Human Papillomavirus (HPV) vaccines will not affect this need for decades to come. Therapeutic vaccinations offers an attractive alternative to the current surgical options for treating premalignant lesions; it can address the underlying viral HPV infection as well as all HPV-associated lesions regardless of location, and induce long-lasting immunity, thus preventing recurrence. |
| |
|
|
